Global Bovine Respiratory Disease Treatment 2017-2021

  • ID: 4143823
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
until May 31st 2018
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bayer HealthCare
  • Boehringer Ingelheim
  • Elanco
  • Inovio Pharmaceuticals
  • Merck
  • Plumbline Life Sciences
  • MORE
About Bovine Respiratory Disease Treatment

Bovine respiratory disease is a multifactorial and complex disorder caused due to a combination of more than one microbial pathogens, inadequate housing conditions, impaired host immunity, and environmental factors.

The analysts forecast the global bovine respiratory disease treatment to grow at a CAGR of 8.11% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global bovine respiratory disease treatment for 2017-2021. To calculate the market size, the report considers the include sales of branded drugs, generic drugs, and vaccines.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Bovine Respiratory Disease Treatment 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Bayer HealthCare
- Boehringer Ingelheim
- Elanco
- Merck
- Zoetis

Other prominent vendors
- Bimeda Group
- Ceva
- Huvepharma
- Inovio Pharmaceuticals
- Med-Pharmex
- Norbrook Laboratories
- Plumbline Life Sciences

Market drivers
- Development of novel products
- For a full, detailed list, view the full report

Market challenges
- High cost of therapies coupled with presence of natural alternatives
- For a full, detailed list, view the full report

Market trends
- Growing focus on the development of combination drugs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer HealthCare
  • Boehringer Ingelheim
  • Elanco
  • Inovio Pharmaceuticals
  • Merck
  • Plumbline Life Sciences
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of bovine respiratory disease

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Market segmentation by product category
  • Antibiotics
  • Vaccines
  • Others
PART 08: Geographical segmentation
  • BRD vaccine market in Americas
  • BRD treatment market in EMEA
  • BRD treatment market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 11: Market trends
  • Growing focus on the development of combination drugs
  • Increase in preventive measures
  • Advancements in technology
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Bayer HealthCare
  • Boehringer Ingelheim
  • Elanco
  • Merck
  • Zoetis
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Global BRD treatment market
Exhibit 02: Global BRD treatment market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis in global BRD treatment market
Exhibit 04: Five forces analysis
Exhibit 05: Market segmentation by product category 2016
Exhibit 06: Important antibiotics prescribed for treatment for BRD
Exhibit 07: Global antibiotics segment in BRD treatment market 2016-2021 ($ millions)
Exhibit 08: Important vaccines for prevention of BRD
Exhibit 09: Global vaccines segment in BRD treatment market 2016-2021 ($ millions)
Exhibit 10: Global others segment in BRD treatment market 2016-2021 ($ millions)
Exhibit 11: Segmentation of global BRD treatment market based on geography 2016 and 2021
Exhibit 12: BRD treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: BRD treatment market in Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: BRD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario in APAC
Exhibit 18: BRD treatment market in APAC 2016-2021 ($ millions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of challenges
Exhibit 21: Competitive structure analysis of global BRD treatment market 2016
Exhibit 22: Competitive analysis of global BRD treatment market
Exhibit 23: Strategic success factors of companies in global BRD treatment market
Exhibit 24: Bayer HealthCare: Key highlights
Exhibit 25: Bayer HealthCare: Strength assessment
Exhibit 26: Bayer HealthCare: Strategy assessment
Exhibit 27: Bayer HealthCare: Opportunity assessment
Exhibit 28: Boehringer Ingelheim: Key highlights
Exhibit 29: Boehringer Ingelheim: Strength assessment
Exhibit 30: Boehringer Ingelheim: Strategy assessment
Exhibit 31: Boehringer Ingelheim: Opportunity assessment
Exhibit 32: Elanco: Key highlights
Exhibit 33: Elanco: Strength assessment
Exhibit 34: Elanco: Strategy assessment
Exhibit 35: Elanco: Opportunity assessment
Exhibit 36: Merck: Key highlights
Exhibit 37: Merck: Strength assessment
Exhibit 38: Merck: Strategy assessment
Exhibit 39: Merck: Opportunity assessment
Exhibit 40: Zoetis: Key highlights
Exhibit 41: Zoetis: Strength assessment
Exhibit 42: Zoetis: Strategy assessment
Exhibit 43: Zoetis: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bayer HealthCare
  • Boehringer Ingelheim
  • Elanco
  • Inovio Pharmaceuticals
  • Merck
  • Plumbline Life Sciences
  • MORE
New Report Released: – Global Bovine Respiratory Disease Treatment 2017-2021

The author of the report recognizes the following companies as the key players in the global bovine respiratory disease treatment: Bayer HealthCare, Boehringer Ingelheim, Elanco, Merck, and Zoetis.

Other Prominent Vendors in the market are: Bimeda, Ceva, Huvepharma, Inovio Pharmaceuticals, Med-Pharmex, Norbrook Laboratories, and Plumbline Life Sciences.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is growing focus on the development of combination drugs. There has been a growing focus of vendors to develop combination drugs that can offer improved efficacy and better treatment outcomes. Traditionally, many drugs have been developed for the treatment of BRD. However, those drugs have been associated with many unmet medical needs. The current treatment options cannot treat the disease completely as BRD is associated with complex etiology.”

According to the report, one of the major drivers for this market is development of novel products. The development of novel products is expected to bring substantial growth opportunities in the market. The launch of new products will substantially increase the adoption rates, thereby driving the market growth. Traditionally, antibiotics and vaccines are typically used for the treatment of BRD. To gain competitive advantage, vendors are focusing on developing novel drugs to drive growth and profitability substantially.

Further, the report states that one of the major factors hindering the growth of this market is high cost of therapies coupled with presence of natural alternatives. The high cost of drugs may hinder the growth prospects in the market. The direct cost of treatment of BRD in feedlot cattle is substantial at $23.60 per case. These costs had almost doubled since 1999 when the cost of treatment was $12.59 per case. The high cost of therapies could be due to the presence of branded products for the treatment of BRD.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bayer HealthCare
  • Boehringer Ingelheim
  • Elanco
  • Merck
  • Zoetis
  • Bimeda
  • Ceva
  • Huvepharma
  • Inovio Pharmaceuticals
  • Med-Pharmex
  • Norbrook Laboratories
  • Plumbline Life Sciences
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll